Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Autologous skeletal muscle-derived cell implantation for fecal incontinence – follow-up open-label study in prior placebo patients
2021-005399-21Phase 2Completed
- Sponsor
- Innovacell
- Start
- Nov 2021
- Modality
- Stem Cell Therapies → Cell Therapies
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of autologous skeletal muscle-derived cells in fecal incontinence (FI), sponsored by Innovacell. Primary endpoint: Change in frequency of fecal incontinence episodes. Started Nov 2021; status: completed.
02
Drugs
autologous skeletal muscle-derived cells
03
Conditions
fecal incontinence (FI)
Beyond the preview
Go deeper on 2021-005399-21.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2021-005399-21.